ATE202552T1 - Benzamide für behandlung von neurodegenerativen störungen - Google Patents

Benzamide für behandlung von neurodegenerativen störungen

Info

Publication number
ATE202552T1
ATE202552T1 AT96911550T AT96911550T ATE202552T1 AT E202552 T1 ATE202552 T1 AT E202552T1 AT 96911550 T AT96911550 T AT 96911550T AT 96911550 T AT96911550 T AT 96911550T AT E202552 T1 ATE202552 T1 AT E202552T1
Authority
AT
Austria
Prior art keywords
benzamide
treatment
neurodegenerative disorders
neurodegenerative
disorders
Prior art date
Application number
AT96911550T
Other languages
English (en)
Inventor
William David Flitter
William A Garland
Allan L Wilcox
Richard E Paylor
Original Assignee
Centaur Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/415,847 external-priority patent/US5643965A/en
Priority claimed from US08/415,248 external-priority patent/US5659082A/en
Priority claimed from US08/415,694 external-priority patent/US5658953A/en
Application filed by Centaur Pharmaceuticals Inc filed Critical Centaur Pharmaceuticals Inc
Application granted granted Critical
Publication of ATE202552T1 publication Critical patent/ATE202552T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
    • C07C237/38—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to a carbon atom of a ring other than a six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C233/65—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
    • C07C237/30—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
    • C07C237/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT96911550T 1995-04-03 1996-04-03 Benzamide für behandlung von neurodegenerativen störungen ATE202552T1 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US41567795A 1995-04-03 1995-04-03
US08/415,847 US5643965A (en) 1995-04-03 1995-04-03 Aminobenzamide compounds for the treatment of neurodegenerative disorders
US08/415,248 US5659082A (en) 1995-04-03 1995-04-03 Nitro- and aminobenzamide compounds for neurodegenerative disorders
US08/415,694 US5658953A (en) 1995-04-03 1995-04-03 Pharmaceutical compositions of acetamidobenzamide compounds for neurodegenerative disorders
PCT/US1996/004538 WO1996031462A1 (en) 1995-04-03 1996-04-03 Benzamides for neurodegenerative disorder treatment

Publications (1)

Publication Number Publication Date
ATE202552T1 true ATE202552T1 (de) 2001-07-15

Family

ID=27503636

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96911550T ATE202552T1 (de) 1995-04-03 1996-04-03 Benzamide für behandlung von neurodegenerativen störungen

Country Status (38)

Country Link
EP (1) EP0819113B1 (de)
JP (1) JP3479658B2 (de)
KR (1) KR100429120B1 (de)
CN (1) CN1073552C (de)
AR (1) AR002978A1 (de)
AT (1) ATE202552T1 (de)
AU (1) AU721045B2 (de)
BG (1) BG63384B1 (de)
CA (1) CA2215166A1 (de)
CO (1) CO4700431A1 (de)
CZ (1) CZ295852B6 (de)
DE (1) DE69613567T2 (de)
DK (1) DK0819113T3 (de)
DZ (1) DZ2012A1 (de)
EA (1) EA002031B1 (de)
EE (1) EE03437B1 (de)
ES (1) ES2160240T3 (de)
GR (1) GR3036466T3 (de)
HR (1) HRP960156B1 (de)
HU (1) HUP9801759A3 (de)
IL (1) IL117629A (de)
IS (1) IS1919B (de)
MA (1) MA23837A1 (de)
MX (1) MX9707596A (de)
MY (1) MY121206A (de)
NO (1) NO318441B1 (de)
NZ (1) NZ306204A (de)
PL (1) PL184121B1 (de)
PT (1) PT819113E (de)
RO (1) RO116190B1 (de)
SA (1) SA96160739B1 (de)
SI (1) SI0819113T1 (de)
SK (1) SK282900B6 (de)
TN (1) TNSN96051A1 (de)
TR (1) TR199701114T1 (de)
TW (1) TW381073B (de)
WO (1) WO1996031462A1 (de)
YU (1) YU21096A (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2252403A1 (en) * 1996-04-17 1997-10-23 William Garland Benzamide treatment of dementia associated with aids virus (hiv-1) infection
DE69828197T2 (de) * 1997-10-27 2005-12-08 Sumitomo Pharmaceuticals Co., Ltd. Amidderivate zur behandlung neurodegenerativer erkrankungen der netzhaut
EP1079820A1 (de) 1998-05-19 2001-03-07 Centaur Pharmaceuticals, Inc. Arzneimittel auf der basis von benzamiden zur behandlung von entzündlichen darmerkrankungen
AU3985699A (en) * 1998-05-19 1999-12-06 Centaur Pharmaceuticals, Inc. Amide therapeutics for the treatment of inflammatory bowel disease
WO2000064430A1 (en) * 1999-04-23 2000-11-02 Sumitomo Pharmaceuticals Co., Ltd. Apoptosis inhibitors
CN101817761B (zh) * 2010-01-29 2014-06-25 浙江大学 苯甲酸酯类衍生物及制备方法和应用
EP2535059A4 (de) * 2010-02-10 2014-03-12 Public Univ Corp Yokohama City Verwendung einer an msin3b bindenden verbindung zur spezifischen bindung an den neuronenrestriktiven silencer-faktor (nrsf)
WO2014155184A1 (en) * 2013-03-28 2014-10-02 Rhenovia Pharma Treatment for parkinson's disease
CN115594603A (zh) * 2022-10-09 2023-01-13 湖北师范大学(Cn) 微通道反应器制备n-叔丁基-4-氨基苯甲酰胺的方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1069882B (it) * 1975-12-22 1985-03-25 Mallinckrodt Inc 3 5 bis acilammino benzammidi particolarmente utili come agenti di contrasto per raffi x e procedimento per la loro preparazione
JPS5721320A (en) * 1980-07-11 1982-02-04 Chugai Pharmaceut Co Ltd Blood sugar level depressing agent
JPS5867657A (ja) * 1981-10-15 1983-04-22 Chugai Pharmaceut Co Ltd ペンズアミド誘導体
US5472983A (en) * 1994-04-14 1995-12-05 Centaur Pharmaceuticals, Inc. Benzamide-containing pharmaceutical compositions

Also Published As

Publication number Publication date
WO1996031462A1 (en) 1996-10-10
NZ306204A (en) 1999-01-28
MY121206A (en) 2006-01-28
AU5440496A (en) 1996-10-23
IS4569A (is) 1997-09-25
TR199701114T1 (xx) 1998-02-21
NO318441B1 (no) 2005-03-21
AR002978A1 (es) 1998-05-27
KR100429120B1 (ko) 2004-08-18
DK0819113T3 (da) 2001-10-15
PL322625A1 (en) 1998-02-02
EP0819113A1 (de) 1998-01-21
CN1182416A (zh) 1998-05-20
HUP9801759A3 (en) 2001-06-28
CZ295852B6 (cs) 2005-11-16
TNSN96051A1 (fr) 2005-03-15
SI0819113T1 (en) 2001-10-31
JPH11501319A (ja) 1999-02-02
EA002031B1 (ru) 2001-12-24
JP3479658B2 (ja) 2003-12-15
HUP9801759A2 (hu) 1998-12-28
RO116190B1 (ro) 2000-11-30
CN1073552C (zh) 2001-10-24
DZ2012A1 (fr) 2002-07-21
HK1016964A1 (en) 1999-11-12
MX9707596A (es) 1998-06-30
ES2160240T3 (es) 2001-11-01
DE69613567T2 (de) 2002-04-18
MA23837A1 (fr) 1996-12-31
SK282900B6 (sk) 2003-01-09
DE69613567D1 (de) 2001-08-02
KR19980703562A (ko) 1998-11-05
EP0819113B1 (de) 2001-06-27
GR3036466T3 (en) 2001-11-30
AU721045B2 (en) 2000-06-22
IL117629A0 (en) 1996-07-23
EE03437B1 (et) 2001-06-15
EA199700287A1 (ru) 1998-04-30
SK132597A3 (en) 1998-09-09
CA2215166A1 (en) 1996-10-10
BG101929A (en) 1998-04-30
NO974569L (no) 1997-11-21
EE9700235A (et) 1998-04-15
PL184121B1 (pl) 2002-09-30
BG63384B1 (bg) 2001-12-29
IS1919B (is) 2004-03-15
HRP960156A2 (en) 1997-10-31
HRP960156B1 (en) 2002-04-30
PT819113E (pt) 2001-10-30
CO4700431A1 (es) 1998-12-29
SA96160739B1 (ar) 2005-10-15
IL117629A (en) 2000-08-13
YU21096A (sh) 1999-03-04
TW381073B (en) 2000-02-01
CZ309897A3 (cs) 1998-12-16
NO974569D0 (no) 1997-10-02

Similar Documents

Publication Publication Date Title
DE59608738D1 (de) Verwendung von epinastin für die behandlung von schmerzen
DE69927823D1 (de) Hydrogel für die therapeutische behandlung von aneurysmas
DE69718731D1 (de) Kombinationstherapie für die Behandlung von Psychosen
DE69829558D1 (de) Sulfonamide für die behandlung von störungen durch endothelin vermittelt
DE69500089D1 (de) Behandlung von Geflügel
DE69737402D1 (de) Vorrichtung zur Behandlung von neurodegenerativen Störungen
EP0792137A4 (de) Pilzhemmende behandlung für die nägel
ATE205365T1 (de) Enzymatische behandlung von kakao
DE69222258D1 (de) Einrichtung und Verfahren für die Behandlung von Aussenwänden
DE69530860D1 (de) Behandlung der entzündung des sehnervs
DE69715631D1 (de) Antikonvulsive sulfamatderivate zur behandlung von fettleibigkeit
ATA76995A (de) Stabiles präparat zur behandlung von blutgerinnungsstörungen
DE69634951D1 (de) Topische verwendung von betulinsäure zur behandlung bösartiger melanome
DE69626539D1 (de) topische Verwendung von Vitamin D zur Behandlung von Augenerkrankungen
DE69526437D1 (de) Transdermal verabreichbare zubereitung zur behandlung von störungen des harnlassens
DE69530486D1 (de) Behandlung von uteriner fibrosis
DE69635708D1 (de) Tetrandrin zur behandlung von augenentzündungen
DE69519577D1 (de) Prednisolonmetasulfobenzoatzusammensetzung zur behandlung von entzündungserkrankung des darmes
DE69501172D1 (de) Einrichtung für die Behandlung von Substrat
ATE221763T1 (de) Die verwendung von glyceryltriacetat zur behandlung von onychomykosen
DE69613567D1 (de) Benzamide für behandlung von neurodegenerativen störungen
DE59801385D1 (de) Durchlaufanlage für die behandlung von werkstücken
DE69521138D1 (de) Behandlung von druckbehältern
DE69735417D1 (de) 2,5-dihydroxybenzylsulfonderivate zur behandlung von sexuellen störungen
DE69327312D1 (de) Deazaaminopterine für behandlung von entzündungen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EEIH Change in the person of patent owner
REN Ceased due to non-payment of the annual fee